New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2012
23:40 EDTESRX, TITN, CELG, BEAM, P, CMG, KORS, STO, TSCO, AGN, SLE, AUQ, DRI, GLD, SHW, HD, COV, CHK, RNDY, WPRTJim Cramer's "Mad Money"
Jim Cramer said, "2012 is no longer about global economic crisis, it's about buying stock in the companies you love." Cramer said he's no longer sweating the details of every story that hits the news wires. Because the big-money players, those who would sell on every bit of negative news, are simply no longer a part of this market. They have been replaced by good old-fashioned individual investors. When companies break up, investors win, Cramer reminded viewers, as he highlighted yet another corporate breakup story, Sara Lee (SLE). He said that shares of Sara Lee should follow in the footsteps of Beam (BEAM) and Covidien (COV), two other breakup stocks, which headed markedly higher. Sara Lee is offering a $3-a-share special dividend to shareholders when the breakup occurs. Additionally, recent analysis of Sara Lee's various components values the stock 22% higher than where it trades today. Sara Lee plans to update shareholders on its progress at an investors meeting on June 5. Investing in Sara Lee will be a slow climb, said Cramer, which is why he would use recent weakness in the stock to get in at attractive prices. Continuing with his week-long series of great American growth stocks, Cramer turned the spotlight onto Allergan (AGN). It is not only a health care company that treats eye problems and migraines, but it is also a leader in medical aesthetics, including Botox and great implants. Cramer said that Allergan has multiple years of growth ahead of it. Its end markets are huge. Also, Allergan is highly competitive in every arena in which it enters and the company pays a tiny dividend. Shares trade for just 19x earnings and the company has a 14% long-term growth rate. Giving investors another great American growth stock, Cramer also highlighted Celgene (CELG), another stock just off its 52-week high. Celgene has one of the fastest growth rates in its sector, said Cramer, and also huge market potential as a host of new products and new applications for existing products are chugging toward FDA approval. Internationally, the company is a powerhouse. Cramer said that while Celgene is unlikely to offer a dividend anytime soon, the company has done a few well-timed stock buybacks to reward shareholders. Celgene sports a rock-solid balance sheet. Celgene trades at just 13.8x next year's earnings, despite the company's 24% growth rate. NO HUDDLE OFFENSE: Cramer said that the tailwinds are all lining up for a great quarter at Home Depot (HD), and he would be a buyer of the stock, even up near its 52-week high. Case-in-point: Tractor Supply (TSCO) announced sales that are double what analysts are expecting and Titan Machinery (TITN) pre-announced strong earnings, followed by Sherwin-Williams (SHW) announcing sales up by 20%. LIGHTNING ROUND: (Bullish) STO; ESRX; GLD; KORS; WPRT; DRI; CMG; RNDY. (Bearish) AUQ; P; CHK. Reference Link
News For SLE;BEAM;COV;AGN;CELG;HD;TSCO;TITN;SHW;STO;ESRX;GLD;KORS;WPRT;DRI;CMG;RNDY;AUQ;P;CHK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
January 12, 2015
11:06 EDTCELGCelgene backs FY17 target for adjusted EPS $7.50, sales $13B-$14B
Subscribe for More Information
11:03 EDTCELGCelgene sees FY15 Revlimid sales $5.6B-$5.7B
Subscribe for More Information
11:02 EDTCELGCelgene sees Q4 adjusted EPS $1.01, consensus 99c
Subscribe for More Information
11:02 EDTCELGCelgene sees FY14 adjusted EPS $3.71, consensus $3.69
Sees FY14 net product sales $7.56B, consensus $7.66B. Sees FY14 Revlimid sales $4.98B, Abraxane sales $848M, Pomalyst/Imnovid sales $680M and Otezla sales $70M.
10:59 EDTCELGCelgene sees FY15 adjusted EPS $4.60-$4.75, consensus $4.84
Subscribe for More Information
10:56 EDTCELGCelgene says no higher priority that accelerating development of Crohn's drug
Subscribe for More Information
10:53 EDTCELGCelgene says Otezla scripts accelerated in Q4
10:51 EDTCELGCelgene reports FY14 EPS $3.71, consensus $3.69
Subscribe for More Information
10:44 EDTCELGCelgene CEO says company expects to meet, exceed 2017 guidance
The company is speaking at JPMorgan's conference.
10:00 EDTSHWOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTSTO, CHKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico-Eagle (AEM) upgraded at BMO Capital... Aimco (AIV) upgraded to Outperform from Market Perform at Wells Fargo... Alaska Air (ALK) upgraded at Evercore ISI... Alcoa (AA) upgraded to Buy from Neutral at Nomura... Alon USA Energy (ALJ) upgraded to Neutral from Sell at Goldman... AvalonBay (AVB) upgraded to Buy from Hold at Jefferies... BASF (BASFY) upgraded to Buy from Neutral at Citigroup... C.H. Robinson (CHRW) upgraded to Overweight from Equal Weight at Barclays... CBS (CBS) upgraded to Outperform at Cowen... Chesapeake (CHK) upgraded to Buy from Neutral at Goldman... China Mobile (CHL) upgraded to Buy from Hold at Jefferies... Chunghwa Telecom (CHT) upgraded to Neutral from Underweight at ... D.R. Horton (DHI) upgraded at KeyBanc... Daimler AG (DDAIF) upgraded to Neutral from Underperform at BofA/Merrill... Diamond Resorts (DRII) upgraded to Buy from Neutral at Goldman... FMC Corporation (FMC) upgraded to Buy from Neutral at BofA/Merrill... First Cash Financial (FCFS) upgraded to Buy from Neutral at Janney Capital... Frontier Communications (FTR) upgraded at BofA/Merrill... HomeAway (AWAY) upgraded to Outperform from Neutral at Macquarie... Ingersoll-Rand (IR) upgraded at Morgan Stanley... KB Home (KBH) upgraded to Outperform from Market Perform at Raymond James... Knight Transportation (KNX) upgraded to Overweight from Equal Weight at Barclays... LabCorp (LH) upgraded to Outperform at RW Baird... M.D.C. Holdings (MDC) upgraded to Outperform from Market Perform at Raymond James... Mid-America Apartment (MAA) upgraded to Buy from Hold at Jefferies... PACCAR (PCAR) upgraded at RBC Capital... Parsley Energy (PE) upgraded to Neutral from Sell at Goldman... Peugeot (PUGOY) upgraded to Buy from Underperform at BofA/Merrill... Radware (RDWR) upgraded to Buy from Neutral at Buckingham... Rush Enterprises (RUSHA) upgraded at BB&T... Ryland Group (RYL) upgraded to Outperform from Market Perform at Raymond James... SL Green Realty (SLG) upgraded to Buy from Hold at Jefferies... Solera (SLH) upgraded to Buy from Neutral at Goldman... Standard Pacific (SPF) upgraded to Neutral from Underweight at JPMorgan... Statoil (STO) upgraded to Neutral from Sell at Goldman... Syngenta (SYT) upgraded to Buy from Hold at Miller Tabak... VMware (VMW) upgraded to Positive from Mixed at OTR Global... Vale (VALE) upgraded to Outperform from Sector Perform at Scotia Capital... Volvo (VOLVY) upgraded to Neutral from Underperform at BofA/Merrill... Windstream (WIN) upgraded at BofA/Merrill... lululemon (LULU) upgraded to Neutral from Underperform at Sterne Agee.
09:37 EDTAGNSupreme Court rejects Allergan appeal on generic Latisse, Bloomberg reports
09:17 EDTSTOStatoil upgraded to Neutral from Sell at Goldman
Subscribe for More Information
09:13 EDTDRIRBC Capital events at 17th Annual ICR XChange Conference
Company Meetings to be held at the 17th Annual ICR XChange Conference in Orlando, Florida on January 12-13.
08:55 EDTDRIBofA/Merrill events at 17th Annual ICR XChange Conference
Company Meetings to be held at the ICR XChange Conference in Orlando, Florida on January 12-13.
08:09 EDTAGNActavis and Allergan announce early termination of HSR waiting period
Subscribe for More Information
08:07 EDTAGNActavis, Allergan announce early termination of Hart Scott Rodino waiting period
Subscribe for More Information
06:22 EDTSHWSherwin-Williams downgraded to Neutral from Buy at UBS
Subscribe for More Information
06:21 EDTCHKChesapeake upgraded to Buy from Neutral at Goldman
Goldman upgraded Chesapeake to Buy given attractive valuation, a strong balance sheet from asset sales, improving asset quality, and new management's focus on capital efficiency. Price target is $23.
06:03 EDTGLDSPDR Gold Trust overall implied volatility at 17; 26-week average is 17
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use